Squarepoint
CADL icon

Squarepoint’s Candel Therapeutics CADL Stock Holding History

Squarepoint’s Portfolio CADL Stock Details CADL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$775K Buy
+75,211
New +$568K ﹤0.01% 3102
2026
Q1 		– Sell
-19,737
Closed -$112K – 4315
2025
Q4 		$112K Sell
19,737
-11,225
-36% -$60.4K ﹤0.01% 4020
2025
Q3 		$158K Sell
30,962
-5,989
-16% -$34.6K ﹤0.01% 4012
2025
Q2 		$187K Sell
36,951
-38,127
-51% -$196K ﹤0.01% 3998
2025
Q1 		$424K Buy
75,078
+55,767
+289% +$456K ﹤0.01% 3459
2024
Q4 		$168K Buy
19,311
+8,962
+87% +$53K ﹤0.01% 4539
2024
Q3 		$71.7K Sell
10,349
-1,889
-15% -$11.7K ﹤0.01% 3939
2024
Q2 		$75.9K Buy
+12,238
New +$91.8K ﹤0.01% 3850

Other funds holding CADL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $2.67B AUM 169.09% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Squarepoint's CADL Position: Q2 2026 in Review

Squarepoint opened a new position in Candel Therapeutics (CADL) in Q2 2026: 75,211 shares worth $775K. The stake represents ﹤0.01% of the portfolio and ranks #3102 among its holdings. This is a return to the name: Squarepoint previously reported a position in CADL as recently as Q4 2025.

Squarepoint first reported a position in CADL in Q2 2024 and has held it in 8 quarters since. 138 funds tracked by Wall St. Rank hold CADL as of Q2 2026.

  • Squarepoint held 75,211 shares of Candel Therapeutics worth $775K as of Q2 2026.
  • Candel Therapeutics was a new Squarepoint position in Q2 2026.
  • Candel Therapeutics made up ﹤0.01% of Squarepoint's portfolio in Q2 2026, its #3102 holding.
  • Squarepoint first reported a position in Candel Therapeutics in Q2 2024 and has held it in 8 quarters since.
  • 138 funds tracked by Wall St. Rank held Candel Therapeutics as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.